Related Experiment Video
Updated: Nov 5, 2025

Subcutaneous Trigeminal Nerve Field Stimulation for Refractory Facial Pain
Published on: May 10, 2017
Medical Management of Trigeminal Neuralgia.
Satish V Khadilkar1, Varsha A Patil2
1Department of Neurology, Bombay Hospital Institute of Medical Sciences, New Marine Lines, Mumbai, Maharashtra, India.
Carbamazepine and oxcarbazepine are first-line treatments for trigeminal neuralgia (TN). Alternative medications and surgical options are available for patients with treatment resistance or intolerance to initial therapies.
Area of Science:
- Neurology
- Pharmacology
Background:
- Trigeminal neuralgia (TN) significantly impacts patient quality of life.
- Effective medical management is crucial for TN patients.
Purpose of the Study:
- To review current and emerging pharmacological treatments for trigeminal neuralgia.
- To discuss treatment strategies for medically refractory TN.
Main Methods:
- Comprehensive literature review of TN pharmacological treatments.
- Searched PubMed, Google Scholar, and Cochrane databases.
- Focused on first-line, second-line, and novel drug therapies.
Main Results:
- Carbamazepine (CBZ) and oxcarbazepine (OXC) are first-line TN drugs.
- 30% of patients show initial resistance; 50% develop resistance over time.
- Second-line options include lamotrigine, baclofen, gabapentin, pregabalin, and Botulinum toxin A; vixotrigine shows promise.
Conclusions:
- CBZ and OXC are primary treatments for TN.
- Combination therapy or alternative drugs are indicated for poor response or adverse events.
- Surgical interventions are recommended for medically intractable cases.
Related Concept Videos
Angina IV: Management
Angina V: Nursing Management
Analgesia and Pain Management
Mitral Stenosis III: Medical Management
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management

